Etanercept
Contents
Description
Etanercept is a fusion protein that acts as a TNF inhibitor by binding to tumor necrosis factor and blocking its interaction with cell surface receptors. It is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients aged 2 years and older. The medication has demonstrated efficacy in controlling inflammation and preventing joint damage.
Indications & Therapeutic Use
polyarticular juvenile idiopathic arthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis
Global Availability (10 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Buy / Source Etanercept — GNH India
28 matching products available through GNH India. Select a product to view details and request a quote on the GNH India website.
Products and ordering are fulfilled by GNH India. You will be redirected to www.gnhindia.com.
Available Through
This drug is available for procurement through the following fulfilment partner.
| Generic Name | etanercept |
| Brands | 1 brand available |
| Active Ingredient | etanercept |
| Drug Class | polyarticular juvenile idiopathic arthritis |
| Manufacturer | Amgen |
| Dosage Forms | subcutaneous injection 25mg, 50mg prefilled syringe; 50mg/mL autoinjector |
| Medical Code | L04AB01 |
| Orphan Status | No |
| Cold Chain | Required |
| Lead Time | 10 days |
| Reg. Status | FDA Approved |
| Clinical Trial | NCT00012506 |
| Countries | 10 countries |